Sementis Ltd Announces New Developments

Sementis has recently announced that over the past few months a number of “proof of concept” experiments have been successfully undertaken demonstrating the following:

1) The attenuated SCV is totally attenuated. That is, the data proves that the platform is non-replicating in mice which is one of the core aspects of the technology.

2) SCV vaccination protects mice from ECTV which is a mouse pox disease. This is the standard test for a vaccine to be considered a smallpox vaccine for humans.

3) Sementis’ Chikungunya vaccine-antigen design has been proven effective in protecting mice against Chikungunya infection – which has reached epidemic proportions in parts of the world.

4) Preliminary results from the peanut vaccine experiments are encouraging and consistent with a shift from an allergic TH2 to a TH1 response post-vaccination which is the primary objective.

Sementis’ Chairman, Maurice O’Shannassy commented,
“Needless to say, that with these results, we are extremely excited about the future and continue discussions with very interested potential global partners”.